TNFSF11 and neoplasm: The mechanistic comprehension of bone turnover in tumor growth has led to the clinical use of osteoclast inhibiting bisphosphonates, and Denosumab (anti-RANKL antibody) in patients with bone metastasis, and has become the standard of care to improve quality of life by limiting bone turnover (Figure 1, step 2) (21).